Summary:
A Spanish (Basque) scientific foundation specialized in R&D and innovation management for the healthcare system seeks a company to license a non-invasive method for the screening, diagnosis or monitoring of colorectal cancer and/or advanced adenoma.
Description:
Colorectal cancer (CRC) is the second leading cause of cancer death in developed countries. Certain studies affirm that detecting precancerous polyps can reduce both colorectal cancer incidence and mortality by 30% and 50% respectively. A colonoscopy is currently considered to be the most accurate test for early detection of CRC, but it has the limitation of causing a low level of adherence in patients due to the discomfort of the test and the preparations required.
This invention provides a new screening and/or diagnostic method, both for the precancerous stage (advanced adenoma) and for CRC, based on identifying the level of certain metabolic markers present in a faeces sample collected from the patient.
Type (e.g. company, R&D institution…), field of industry and Role of Partner Sought:
The Spanish (Basque) organization is offering a license agreement to experienced companies in preclinical and clinical development of medical devices and diagnostic kits interested in acquiring this technology. Moreover, this license offer seeks both options: On the one side, companies willing to commercialise, but also companies interested in enhancing the invention.
It would be preferable for the partner to be a healthcare facility so that the validation of the method can be carried out. Nevertheless, this is not compulsory.
Stage of Development:
Under development/lab tested
IPR Status:
Patent(s) applied for but not yet granted
Comments Regarding IPR Status:
European Patent Application
USA & Canada
External code:
TOES20210204001
